Stryker (NYSE:SYK) had its price objective boosted by JPMorgan Chase & Co. to $200.00 in a research note published on Thursday morning, The Fly reports. They currently have an overweight rating on the medical technology company’s stock.

Several other equities analysts have also commented on the stock. Citigroup upped their price target on shares of Stryker from $171.00 to $173.00 and gave the stock a neutral rating in a research report on Wednesday, July 25th. BMO Capital Markets reaffirmed a hold rating and set a $174.00 price target on shares of Stryker in a research report on Thursday, July 12th. Zacks Investment Research lowered shares of Stryker from a buy rating to a hold rating in a research report on Thursday, May 24th. Royal Bank of Canada reaffirmed a buy rating and set a $184.00 price target on shares of Stryker in a research report on Wednesday, July 25th. Finally, Canaccord Genuity reaffirmed a buy rating and set a $185.00 price target on shares of Stryker in a research report on Wednesday, July 25th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $178.33.

NYSE:SYK opened at $170.50 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.83 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $64.81 billion, a PE ratio of 25.04, a PEG ratio of 2.43 and a beta of 0.59. Stryker has a 1-year low of $138.94 and a 1-year high of $179.84.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, July 24th. The medical technology company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.73 by $0.03. The business had revenue of $3.32 billion during the quarter, compared to analyst estimates of $3.31 billion. Stryker had a net margin of 8.28% and a return on equity of 26.93%. The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.53 earnings per share. research analysts anticipate that Stryker will post 7.25 earnings per share for the current fiscal year.

In other news, VP Katherine Ann Owen sold 37,866 shares of the stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total value of $6,317,563.44. Following the completion of the sale, the vice president now owns 11,367 shares of the company’s stock, valued at $1,896,470.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.40% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the company. HRT Financial LLC purchased a new position in shares of Stryker in the second quarter valued at $210,000. Truvestments Capital LLC purchased a new position in shares of Stryker in the second quarter valued at $338,000. HM Payson & Co. boosted its stake in shares of Stryker by 6.2% in the second quarter. HM Payson & Co. now owns 7,653 shares of the medical technology company’s stock valued at $1,292,000 after purchasing an additional 446 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of Stryker by 1.5% in the second quarter. Advisors Asset Management Inc. now owns 33,452 shares of the medical technology company’s stock valued at $5,649,000 after purchasing an additional 494 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its stake in shares of Stryker by 0.7% in the second quarter. Public Employees Retirement System of Ohio now owns 236,347 shares of the medical technology company’s stock valued at $39,910,000 after purchasing an additional 1,722 shares during the period. 75.08% of the stock is owned by institutional investors.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Technical Analysis of Stocks, How Can It Help

The Fly

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.